Technical Analysis for ORGS - Orgenesis Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.00 | -52.61% | -1.11 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -52.61% | |
| Volume Surge | Other | -52.61% | |
| Lower Bollinger Band Walk | Weakness | -52.61% | |
| New 52 Week Low | Weakness | -52.61% | |
| Wide Bands | Range Expansion | -52.61% | |
| Below Lower BB | Weakness | -52.61% | |
| Gapped Down | Weakness | -52.61% | |
| Oversold Stochastic | Weakness | -52.61% | |
| NR7 | Range Contraction | -69.12% | |
| Narrow Range Bar | Range Contraction | -69.12% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Gapped Down (Full) | 1 day ago |
| Down 5% | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 11/11/2024
Orgenesis Inc. Description
Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Diabetes Clinical Development Stem Cell Cell Therapy Endocrine System Insulin Hormones Regenerative Medicine Contract Manufacturing Peptide Hormones Contract Manufacturing Services Type I Diabetes Assay Development Services Diabetes Mellitus Type 1 Medicinal Product Medicinal Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.799 |
| 52 Week Low | 1.9283 |
| Average Volume | 32,858 |
| 200-Day Moving Average | 5.63 |
| 50-Day Moving Average | 5.73 |
| 20-Day Moving Average | 3.89 |
| 10-Day Moving Average | 3.42 |
| Average True Range | 0.60 |
| RSI (14) | 27.54 |
| ADX | 30.78 |
| +DI | 13.22 |
| -DI | 39.62 |
| Chandelier Exit (Long, 3 ATRs) | 3.94 |
| Chandelier Exit (Short, 3 ATRs) | 3.74 |
| Upper Bollinger Bands | 5.23 |
| Lower Bollinger Band | 2.55 |
| Percent B (%b) | -0.16 |
| BandWidth | 68.84 |
| MACD Line | -0.77 |
| MACD Signal Line | -0.69 |
| MACD Histogram | -0.0758 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.77 | ||||
| Resistance 3 (R3) | 2.79 | 2.58 | 2.66 | ||
| Resistance 2 (R2) | 2.58 | 2.41 | 2.57 | 2.63 | |
| Resistance 1 (R1) | 2.34 | 2.30 | 2.46 | 2.33 | 2.59 |
| Pivot Point | 2.14 | 2.14 | 2.19 | 2.13 | 2.14 |
| Support 1 (S1) | 1.90 | 1.97 | 2.02 | 1.89 | 1.63 |
| Support 2 (S2) | 1.69 | 1.86 | 1.69 | 1.59 | |
| Support 3 (S3) | 1.46 | 1.69 | 1.56 | ||
| Support 4 (S4) | 1.45 |
